- Home
- CNOBP vs GALT Comparison
CNOBP vs GALT Comparison
Compare CNOBP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOBP | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 493 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 232.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CNOBP | GALT |
|---|---|---|
| Price | $24.19 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | N/A | ★ 522.8K |
| Earning Date | N/A | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.73 |
| 52 Week High | N/A | $7.13 |
Technical Indicators
Market Signals| Indicator | CNOBP | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 33.77 |
| Support Level | $24.16 | $6.03 |
| Resistance Level | $24.24 | $7.13 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 75.00 | 5.41 |
Price Performance
Historical ComparisonAbout CNOBP ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.